Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Estrone-3-sulfate** is a naturally occurring estrogenic steroid and the sulfate ester of estrone. It is both a metabolite and circulating reservoir form of estrogens in humans, acting mainly as a prodrug that is converted via steroid sulfatase into active estrone and, subsequently, to estradiol. Pharmacodynamically, estrone-3-sulfate acts as a **prodrug of estradiol and estrone**, which are potent agonists of the estrogen receptor. The drug is mainly used in menopausal hormone therapy and can be administered alone (as estropipate) or as a component of conjugated or esterified estrogens for indications such as menopausal symptom management, treatment of some forms of infertility, underdeveloped female sexual characteristics, atrophic vaginitis, certain breast cancers (in men and postmenopausal women), prostate cancer, and osteoporosis prevention. It can be administered orally, and in some combination products via transdermal, vaginal, and injectable routes[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estrone-3-sulfate.